Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199645
Abstract: Introduction: Emicizumab is the first bispecific factor IXa- and factor X-directed antibody approved in the US for routine prophylaxis in adult and pediatric people with hemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors.… read more here.
Keywords: real world; adherence; world adherence; pwha ... See more keywords
Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200784
Abstract: Introduction: The safety and effectiveness of emicizumab, a bispecific factor IXa- and factor X-directed antibody approved for routine prophylaxis in adult and pediatric people with hemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors,… read more here.
Keywords: survey; real world; receiving emicizumab; pwha ... See more keywords
Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200872
Abstract: Introduction: Extended half-life (EHL) recombinant factor VIII with Fc-fusion protein (rFVIIIFc) has been launched in Taiwan since 2018. In the past, for standard half life (SHL) FVIII prophylaxis in severe-type people with hemophilia A (PwHA),… read more here.
Keywords: prophylaxis; trough level; trough levels; rfviiifc ... See more keywords
Real-World Use of Efanesoctocog Alfa in Adult Patients with Hemophilia a Including Those with a History of Factor VIII Inhibitor
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-203996
Abstract: Introduction: Efanesoctocog alpha (Efa), a factor VIII replacement therapy independent of von Willebrand factor, is approved for patients with hemophilia A (PwHA). The goal of this study was to report “real world” post-licensure experience treating… read more here.
Keywords: history; factor; factor viii; inhibitor ... See more keywords